Vericel Corp
VCEL Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$43.27
KIRA · Stoqly’s AI analyst, in plain words
- Vericel Corp had $276M of revenue in fiscal 2025, up 16.5% on the year before. Over five years, revenue changed +17.3% a year on average.
- Its operating margin was 4.0%, up 2.1 pts: of every 100 in sales, about 4 is left after running the business.
- Vericel Corp made $16.5M of net profit in fiscal 2025.
- Free cash flow was $24.7M in fiscal 2025, 9.0% of revenue.
Market cap
$2.3B
P/E
90.1x
Revenue
$276M
Net income
$16.5M
Free cash flow
$24.7M
Operating margin
4.0%
Vericel Corp in 30 seconds · fiscal 2025
Are sales growing?
+16.5%
Yes. Sales grew 16.5% last year.
Does it make a profit?
6.0%
A little. It keeps 6.0% of every sale as profit.
Does profit turn into cash?
9.0%
Partly. 9.0% of sales ends up as free cash.
How healthy are the accounts?
7 / 8
Solid. It passes 7 of 8 health tests.
How is the share priced?
90.1x
One share costs 90.1 times its yearly profit per share.
What Vericel Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Vericel Corp
- CIK
- 0000887359
Vericel Corp · VCEL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $156M | $164M | $198M | $237M | $276M |
| Revenue growth | 25.8% | 5.2% | 20.2% | 20.1% | 16.5% |
| Gross margin | 67.9% | 66.8% | 68.6% | 72.6% | 74.4% |
| Operating margin | −5.0% | −10.4% | −3.3% | 1.9% | 4.0% |
| Net income | −$7.5M | −$16.7M | −$3.2M | $10.4M | $16.5M |
| Net margin | −4.8% | −10.2% | −1.6% | 4.4% | 6.0% |
| Diluted EPS | −$0.16 | −$0.35 | −$0.07 | $0.20 | $0.32 |
| Cash | |||||
| Cash from operations | $29.0M | $17.7M | $35.3M | $58.2M | $51.9M |
| Capital expenditure | $7.9M | $7.6M | $20.0M | $64.0M | $27.2M |
| Free cash flow | $21.1M | $10.1M | $15.3M | −$5.8M | $24.7M |
| FCF margin | 13.5% | 6.1% | 7.7% | −2.4% | 9.0% |
| Share count change | −1.7% | 1.4% | 1.0% | 8.6% | 0.9% |
| Debt and strength | |||||
| Cash and short-term investments | $103M | $120M | $110M | $116M | $137M |
| Shareholders' equity | $170M | $192M | $226M | $292M | $355M |
| Current ratio | 6.1x | 5.0x | 4.5x | 4.2x | 5.0x |
| Interest coverage | −1,963.5x | −46.6x | −10.8x | 7.4x | 17.5x |
| Returns and quality | |||||
| Return on equity | −4.9% | −9.2% | −1.5% | 4.0% | 5.1% |
| Return on tangible equity | −4.4% | −9.0% | −1.5% | 3.6% | 4.7% |
| Piotroski F-score | 6 | 2 | 4 | 5 | 7 |
| Altman Z'' | 0.7 | 0.9 | 1.0 | 1.8 | 3.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$7.7M
8 insiders
Of sales under plans
93%
$7.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Vericel Corp · VCEL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $43.27 a share, the company is worth $2.3B: 90.1 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0000887359). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.